PD-L1 – Talk Bio

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

6 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

7 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

7 days ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody

7 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, BioNTech, Biotheus, BNT327/PM8002, Cancer Therapeutic Procedure, Neoplasms, PD-L1, Vascular Endothelial Growth Factor A

BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition

FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression

8 months ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, Immunotherapy, Keytruda, Malignant neoplasm of stomach, PD-L1, Tevimbra, United States Food and Drug Administration

FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra

FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression

8 months ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, nivolumab, PD-L1, PDCD1 gene, pembrolizumab, restrictions, tislelizumab, United States Food and Drug Administration

PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab

FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression

9 months ago talkbio0Tagged Biological Markers, Drug Approval, Esophageal Neoplasms, Gene Expression, inhibitors, Malignant neoplasm of stomach, Neoplasms, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval

FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy

9 months ago talkbio0Tagged Approved, atezolizumab, Enhanze drug delivery technology, Hyaluronidase-tqjs, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous, Tecentriq, United States Food and Drug Administration

Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology

Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options

9 months ago talkbio0Tagged Approved, Enhanze Drug Delivery, Halozyme, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous administration, Tecentriq, Technology, United States Food and Drug Administration

Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology

Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%

9 months ago talkbio0Tagged Akeso, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-L1, pembrolizumab, Phase 3 trial, Positive, summit

Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.